Difference between revisions of "BRAF mutation"

BRAF mutation (view source)

47 bytes added , 18:15, 23 January 2019

no edit summary

48,720

edits

@@ Line 3: / Line 3: @@
 ==General==
 *BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal  | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref>
-**BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
-**BRAF mutations in ~ 10% of colorectal tumours.
+Prevalence by tumour type:<ref name=pmid29148538/>
-***Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
+*BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
-**BRAF mutations in ~45-50% of papillary thyroid carcinoma.
+*BRAF mutations in ~ 10% of colorectal tumours.
-**BRAF mutations in ~3% of [[lung adenocarcinoma]]s.
+**Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
+*BRAF mutations in ~45-50% of papillary thyroid carcinoma.
+*BRAF mutations in ~3% of [[lung adenocarcinoma]]s.
 ==References==